Skip to main content
Sign In
 

Richer Lab


Contacts:

RC1 North  5th Floor P18-5127
Ph. 303 724-3735 office 303 724-3711 lab
 
Research Summary:  

The Richer lab examines functional differences between hormone dependent and independent cancers (breast, endometrial and ovarian) and new endocrine therapy approaches. We also study how non-coding RNAs affect differentiation state in the normal mammary gland and breast cancer, dictating the timing and cell specificity of hormone action including control of aspects of tumor metabolism and the anti-tumor immune response.
 
Areas of Current Research:

2015/7/1-2020/6/31 
1 R01 CA187733-01 NIH NCI Androgen Receptor and Intersecting Pathways Critical in Breast Cancer Subtypes
Richer, Jennifer K (PI) 
Major goals: Androgen receptors and intersecting pathways critical to breast cancer subtypes.
Identify the molecular pathways whereby androgen receptors affect the three main subtypes of breast cancer.
 
2013/08/01-2018/07/31 
DOD BC120183 W81XWH-13-1-0090, DOD Breast Cancer Research Program Clinical Translational Award Targeting Androgen Receptor in Breast Cancer: Enzalutamide as a Novel Breast Cancer Therapeutic
Richer, Jennifer K (PI) 
Major goal: To determine whether enzalutamide can inhibit breast cancer progression.
 
2015/04/01-2018/03/30 
DOD W81XWH-15-1-0039 Breakthrough Level 2, Targeting Tryptophan Catabolism: A Novel Method to Block Triple Negative Breast Cancer Metastasis
Richer, Jennifer K (PI) 
Major goal: Major goal: To determine if TDO2 is the major mechanism for tryptophan catabolism in triple negative breast cancer and if  Kyn binding to AhR elicits both autocrine survival signals in the tumor cells as well as paracrine immune-suppressive effects.
 
2016/09/30- 2019/09/29 
DOD BCRP - Breakthrough Level 1 BC151357P1 W81XWH-16-1-0422 Molecular modeling of estrogen receptor alpha mutated breast cancer to guide new therapeutic strategies
Richer, Jennifer K (Partnering PI) Initiating PI Jay Gertz
Major goals: Discover the molecular and phenotypic consequences of mutations in the ligand binding domain of estrogen receptor and measure the efficacy of anti-androgens and bromodomain inhibitors in blocking the growth of ESR1 mutant breast cancer.
 
10/1/2016-9/30/2018 
Richer, Jennifer K (PI) 
RNA Bioscience Initiative: Dean’s Transformative Research Initiative
Major goals: Inhibiting the lncRNA MALAT1 in ovarian cancer to deliver a higher amount of naked ASO in vivo or try ASO delivered with a non-toxic lipid delivery again but earlier than we did in the first experiment and with and without chemotherapy to determine if it makes the tumors more sensitive to apoptosis induced by paclitaxel.
 
1/1/2017-12/31/2019 
ACS-IRG-16-184-56 
Richer, Jennifer K (PI) 
American Cancer Society –Institutional Research Grant for junior faculty cancer related pilot projects.
Major Goal: Direct the program with co-PI John Tentler to oversee the review process and with the review panel, choose which junior faculty pilot project grants get supported by this ACS grant to the University of Colorado Cancer Center.
 
Active Trainee Grants:

Lisa Greene- NIH NCI NRSA F31 CA203486-01A1
Jessica Christenson, Ph.D. - Cancer Biology Graduate Program T32 Fellowship
Emmanuel Rosas – NIH R01CA187733-02S1 Research supplement to support 

Past Funding: 
Past Training grants:
Diana Cittelly DOD postdoctoral fellowship
Erin Howe NCI NRSA 
Valerie Barton NCI NRSA 
Thomas Rogers – NIH NCI 1F99/K00 CA212230-01 (Pre- to Postdoctoral Fellow Transition Award)
Rick Heinz, CCTSI 
Nicholas D’Amato, postdoctoral American Cancer Society Grant

P01 PAR-10-245, NIH NICHD
Role: Richer, Jennifer K Co-Investigator, PI project 3 Anderson, SM (PI) 
Title: Functional Development of the Mammary Gland
Performance Period: 2011/07/01-2016/06/30
Goal: To elucidate the function of microRNA during secretory activation in the mammary gland.
 
BC122994- W81XWH-12-BCRP-IDEX, DOD BCRP- Idea Expansion Award
Role: Richer, Jennifer K (PI) 
Title: Reversing Anoikis Resistance in Triple Negative Breast Cancer
Performance Period: 2013/10/01-2016/09/30 (including 1 year no cost extension)
Goal: miR-200c and miR-222 are responsible for the dedifferentiated phenotype and aggressive behavior of TNBC.


RicherLab_11-2016_DSC_0087_web.jpg
ScreenHunter_01 Nov. 08 09.32.jpg

Richer Lab - Best.JPG 

Richer Lab - Echo Lake.JPG 
Richer Lab - With Alison.jpg 
Recent Publications:

D’Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Nemkov TG, Spoelstra NS, Hansen KC, and JK.Richer A TDO2-AhR Signaling axis is upregulated in suspension and regulates metastatic phenotypes in triple-negative breast cancer. CANCER RESEARCH 2015 Nov 1;75(21):4651-64 PMID: 26363006

Spoelstra NS, Cittelly DM, Christenson JL, Gordon MA, Elias A, Jedlicka P, and Richer JK. Evaluation of Dicer Expression in Estrogen Receptor alpha Positive versus Triple-Negative Breast Cancer: An Antibody Comparison. HUMAN PATHOLOGY. 2016. May 31. S0046-8177(16)30095-8

D’Amato NC, Jacobsen BM, Gordon MA, Babbs BL, Spoelstra NS, Carson Butterfield KT, Barton VN, Rogers TJ, Sartorius CA, Elias AD, Gertz, J and JK Richer.  Cooperative Dynamics of AR and ER Activity in Breast Cancer. MOLECULAR CANCER RESEARCH 2016 Nov;14(11):1054-1067. PMID: 27565181

Heinz RE, Rudolph MC, Ramanathan P, Spoelstra NS, Butterfield KT, Webb PG, Babbs BL, Gao H, Chen S, Gordon MA, Anderson SM, Neville MC, Gu H, Richer JK (2016). Constitutive expression of microRNA-150 in mammary epithelium suppresses secretory activation and impairs de novo lipogenesis. DEVELOPMENT 2016 Oct 11. PMID: 27729410

Christenson JL, Butterfield KT, Spoelstra NS, Norris JD, Josan JS, Pollock JA, McDonnell DP, Katzenellenbogen BS, Katzenellenbogen JA, and JK Richer. MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. HORMONES AND CANCER. 2017 Apr;8(2):69-77.PMID: 28194662

Gordon MA, D'Amato NC , Gu H , Babbs B, Wulfkuhle JD , Petricoin EF, Gallagher RI, Dong T, Torkko KC, Liu B , Elias A and JK Richer Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer. MOLECULAR CANCER THERAPEUTICS. 2017 Jul;16(7):1389-1400.  PMID: 28468774

Barton VN., Christenson JL, Rogers TJ, Butterfield K, Babbs B, Spoelstra NS, D’Amato NC, Elias A, and JK Richer. Androgen receptor supports an anchorage independent, cancer stem cell like population in triple negative breast cancer. CANCER RESEARCH. 2017 Jul 1;77(13):3455-3466. PMID: 28512248